Cabozantinib, a small-molecule multi-tyrosine kinase inhibitor targeting kinases such as VEGFR2, MET/HGF, AXL, MER, and TYRO3, has demonstrated antitumor activity in the preclinical CRC model. Here, KDR is linked to colorectal carcinoma.